Ceapro Inc. Announces Successful Completion of Collaborative Research and Development Program with University of Alberta
– Project significantly advances broadening the application and utility of Ceapro’s proprietary, first-in-class technologies to develop innovative delivery systems composed of new chemical
– New PGX-based products developed under the collaboration paves the way for commercial scale production of new chemical complexes and innovative delivery systems –
– Potential for applications in personal care, functional food, dietary supplement and pharmaceuticals –
– Findings to be presented at the upcoming 18th European Meeting on Supercritical Fluids –
EDMONTON, Alberta, April 08, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the successful completion of its long-term research project with Professor Dr. Feral Temelli at the University of Alberta (UofA). Based on the successful results of the project, Ceapro will expand the utilization of the PGX Technology and generate innovative high-value ingredients with a competitive advantage, targeting applications in functional food, dietary supplement, personal care, and pharmaceuticals.
The collaborative project titled “PGX technology for drying of biopolymers and their impregnation with bioactives” was initiated in June 2017 and leveraged funding with the Collaborative Research and Development (CRD) grant project from the Natural Sciences and Engineering Research Council of Canada (NSERC). The goal of the project was to expand the array of PGX-processed polymers impregnated with bioactives based on a solid understanding of their behavior under the PGX processing conditions and the interactions between them.
"This project allowed for the screening of various compounds and the retention of the most promising ones with the best marketing potential. With these important findings, we have established an expanded PGX-based product pipeline further supporting the investment decision for the commercial scale up of the PGX Technology for the processing of oat beta glucan, yeast beta glucan and alginate. These first three products offer potential benefits either as stand-alone products or as carrier for other bioactives. We are very grateful to Professor Dr. Feral Temelli, her research team at the UofA, and Ceapro’s research team for the success in this extensive collaborative research project,” commented Mr. Gilles Gagnon, President and Chief Executive Officer of Ceapro.